Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial
Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial
复制标题
DOI：
10.1111/j.1464-410x.2004.04763.x
复制
发表时间：
2004-01-01
影响因子：
4.5
通讯作者：
Gardiner, RA
中科院分区：
文献类型：
--
作者：
Green, HJ;Pakenham, KI;Gardiner, RA
探讨非局限性前列腺癌不同治疗策略对男性生活质量和认知功能的影响。患有前列腺癌的男性被随机分配到四个治疗组中的一个：leuprorelin、goserelin、cyproterone acetate （CPA）或密切临床监测。在重复测量设计中，男性在治疗前（基线）和治疗6个月和12个月后进行评估。一组没有前列腺癌的同龄男性参加了同样长的时间。这些男性是从大学教学医院的公立和私立泌尿科招募的。所有符合激素治疗条件的前列腺癌患者都没有需要立即治疗的症状。总共有82名患者被随机分组，62名患者完成了为期1年的研究，在20名社区参与者中，15名患者完成了研究。主要结果测量来自情绪困扰、存在满意度、身体功能和症状、社会和角色功能、主观认知功能和性功能的问卷调查，并结合记忆、注意力和执行功能的标准神经心理测试。接受雄激素抑制治疗的患者性功能障碍增加，而接受CPA或密切临床监测的患者情绪困扰增加。与治疗前相比，有证据表明leuprorelin、goserelin和CPA对认知功能有不良影响。在决定前列腺癌雄激素抑制治疗的时机时，应考虑对生活质量和认知功能的潜在不良影响。
To investigate the effects of different management strategies for non-localized prostate cancer on men's quality of life and cognitive functioning.Men with prostate cancer were randomly assigned to one of four treatment arms: leuprorelin, goserelin, cyproterone acetate (CPA), or close clinical monitoring. In a repeated-measures design, men were assessed before treatment (baseline) and after 6 and 12 months of treatment. A community comparison group of men of the same age with no prostate cancer participated for the same length of time. The men were recruited from public and private urology departments from university teaching hospitals. All those with prostate cancer who were eligible for hormonal therapy had no symptoms requiring immediate therapy. In all, 82 patients were randomized and 62 completed the 1-year study, and of the 20 community participants, 15 completed the study. The main outcome measures were obtained from questionnaires on emotional distress, existential satisfaction, physical function and symptoms, social and role function, subjective cognitive function, and sexual function, combined with standard neuropsychological tests of memory, attention, and executive functions.Sexual dysfunction increased for patients on androgen-suppressing therapies, and emotional distress increased in those assigned to CPA or close clinical monitoring. Compared with before treatment there was evidence of an adverse effect of leuprorelin, goserelin, and CPA on cognitive function.In deciding the timing of androgen suppression therapy for prostate cancer, consideration should be given to potential adverse effects on quality of life and cognitive function.